Arthur Brothag

Arthur Brothag is a Partner at Apax Partners and, since 2023, the firm's Global Head of Investor Relations and Strategy, based in the London office. He joined Apax in 2009 as a member of the firm's Healthcare investment team, where he spent roughly a decade sourcing and executing deals before moving into his current firm-wide IR and strategy leadership role. Apax is one of the longest-established private equity houses in Europe, focused on large-cap and growth investments across Healthcare, Tech, Services, and Internet/Consumer — a profile that is materially different from the "angel investor / seed round" label in the original stub, which appears to be a data error.

Brothag's path into investing is unusual. He originally trained and practiced as a medical doctor, earning a medical degree and completing doctoral research at the Technical University of Munich (Technische Universität München). He held resident physician positions at university hospitals in Germany and Switzerland, working in internal medicine with a focus on cardiology and oncology. He later earned an MBA (with distinction) from INSEAD.

Before Apax, Brothag built his finance career in London, first as an investment banker at Morgan Stanley and then as an investor on the healthcare team at private equity firm Warburg Pincus. That combination of clinical training and healthcare-focused banking and PE experience made him a natural fit for Apax's healthcare franchise.

Over his years on the Apax healthcare team he participated in and sat on the boards of several notable portfolio companies. In his current capacity as Global Head of IR and Strategy, his mandate is oriented toward the firm's limited partners (fundraising, investor relations) and overall firm strategy rather than sourcing new venture-stage deals.

• Historically a healthcare-focused private equity investor at Apax — medtech, pharma/specialty pharma, diagnostics, and healthcare services — leveraging a clinical background as a former physician.
• Apax typically pursues control buyouts and growth equity in established, scaled businesses, not seed/angel-stage startups; check sizes and enterprise values run to the hundreds of millions to billions, funded from multi-billion-dollar flagship funds.
• His own framing emphasizes teamwork: *"Working as part of a team, whether as a medical doctor or as an investor, has always been core to my professional life."*
• In his current role, his "focus" is on investor relations and firm strategy — engaging limited partners and shaping fund positioning — rather than making individual investment decisions.